EU
Emory University Portfolio holdings
AUM
$27.7M
This Quarter Return
+3.88%
1 Year Return
+31.53%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
(+7.6%)
Cap. Flow
+$12M
Cap. Flow
% of AUM
7.96%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
53
New
7
Increased
21
Reduced
13
Closed
7
Top Buys
| 1 |
JD.com
JD
|
$10.6M |
| 2 |
Heron Therapeutics
HRTX
|
$3.28M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
$2.89M |
| 4 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$2.83M |
| 5 |
TG Therapeutics
TGTX
|
$2.57M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$2.78M |
| 2 |
Puma Biotechnology
PBYI
|
$2.66M |
| 3 |
ABLX
Ablynx NV American Depositary Shares
ABLX
|
$2.63M |
| 4 |
Travere Therapeutics
TVTX
|
$2.57M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$2.44M |
Sector Composition
| 1 | Healthcare | 47.81% |
| 2 | Financials | 29.15% |
| 3 | Consumer Discretionary | 10.46% |
| 4 | Industrials | 2.95% |
| 5 | Communication Services | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class A
BRK.A
$1.09T
| $33M | 21.9% | 117 | – | – |
|
|
2
JD.com
JD
$44.1B
| $15.5M | 10.28% | 397,578 +273,088 | +219% | +$10.6M |
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.56M | 2.36% | 89,951 +1,489 | +2% | +$58.8K |
|
|
GHDX
4
DELISTED
Genomic Health, Inc.
GHDX
| $3.55M | 2.36% | 70,470 -9,121 | -11% | -$460K |
|
|
5
Heron Therapeutics
HRTX
$207M
| $3.28M | 2.18% | +84,475 | New | +$3.28M |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.1M | 2.06% | 46,734 -1,345 | -3% | -$89.3K |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $3.08M | 2.05% | 69,746 +6,247 | +10% | +$276K |
|
|
ABMD
8
DELISTED
Abiomed Inc
ABMD
| $2.89M | 1.92% | +7,065 | New | +$2.89M |
|
|
TFCF
9
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $2.86M | 1.9% | 58,010 +792 | +1% | +$39K |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.84M | 1.89% | 30,190 -633 | -2% | -$59.6K |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $2.84M | 1.89% | 182,043 +9,377 | +5% | +$146K |
|
|
ECYT
12
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $2.83M | 1.88% | +205,295 | New | +$2.83M |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $2.83M | 1.88% | 28,819 -1,906 | -6% | -$187K |
|
|
MYOV
14
DELISTED
Myovant Sciences Ltd.
MYOV
| $2.81M | 1.87% | 123,055 -53,332 | -30% | -$1.22M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $2.74M | 1.82% | 22,081 +288 | +1% | +$35.8K |
|
16
Ascendis Pharma
ASND
$11.8B
| $2.7M | 1.79% | 40,528 -6,405 | -14% | -$426K |
|
17
Incyte
INCY
$16.5B
| $2.67M | 1.77% | 39,831 +9,384 | +31% | +$629K |
|
18
Wave Life Sciences
WVE
$1.53B
| $2.6M | 1.72% | 67,925 +20,039 | +42% | +$766K |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $2.59M | 1.72% | 26,256 +4,940 | +23% | +$487K |
|
|
20
TG Therapeutics
TGTX
$4.65B
| $2.57M | 1.71% | +195,463 | New | +$2.57M |
|
21
InflaRx
IFRX
$108M
| $2.5M | 1.66% | 77,554 -13,207 | -15% | -$426K |
|
22
KKR & Co
KKR
$124B
| $2.47M | 1.64% | 99,559 +4,222 | +4% | +$105K |
|
|
GBT
23
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.46M | 1.63% | 54,317 +12,707 | +31% | +$574K |
|
|
LJPC
24
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $2.43M | 1.61% | 83,163 +5,828 | +8% | +$170K |
|
25
Bread Financial
BFH
$3.09B
| $2.43M | 1.61% | 10,400 +1,738 | +20% | +$405K |
|